Oncology Institute Inc Cash Flow Conversion Efficiency
Oncology Institute Inc cash flow conversion efficiency. Based on the latest financial reports, Oncology Institute Inc (TOI) has a cash flow conversion efficiency ratio of 0.136x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.21 Million) by net assets ($-16.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oncology Institute Inc (2019–2025)
Cash flow conversion efficiency of Oncology Institute Inc from 2019 to 2025. This chart illustrates how Oncology Institute Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Oncology Institute Inc stock price for real-time trading data and today's change.
Oncology Institute Inc Cash Flow Conversion Ratio Explained
Oncology Institute Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oncology Institute Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncology Institute Inc ranked by their cash flow conversion efficiency. Also see TOI market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BlackRock MIT II
NYSE:BLE
|
-0.063x |
|
COOR Service Management AB
ST:COOR
|
0.050x |
|
BOKU INC. REG S DL-0001
F:B04
|
N/A |
|
Changhong Meiling Co Ltd
SHE:000521
|
-0.004x |
|
Zhuhai Huajin Capital Co Ltd
SHE:000532
|
0.026x |
|
China Merchants Port Group Co Ltd
SHE:201872
|
0.012x |
|
Stylam Industries Limited
NSE:STYLAMIND
|
0.104x |
|
Lem Holding SA
SW:LEHN
|
0.074x |
Annual Cash Flow Conversion Efficiency for Oncology Institute Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Oncology Institute Inc from 2019 to 2025. Review TOI cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-15.72 Million | $-24.59 Million | 1.564x | +121.15% |
| 2024-12-31 | $3.59 Million | $-26.54 Million | -7.394x | -1061.11% |
| 2023-12-31 | $57.02 Million | $-36.31 Million | -0.637x | -27.02% |
| 2022-12-31 | $123.17 Million | $-61.76 Million | -0.501x | -59.80% |
| 2021-12-31 | $104.16 Million | $-32.68 Million | -0.314x | -1835.57% |
| 2020-12-31 | $28.10 Million | $508.00K | 0.018x | -78.89% |
| 2019-12-31 | $42.22 Million | $3.62 Million | 0.086x | -- |
About Oncology Institute Inc
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as edu… Read more